The FDA approved niraparib and abiraterone acetate plus prednisone for BRCA2-mutated mCSPC, based on the AMPLITUDE trial's rPFS results. FDA approves a new treatment combining niraparib and ...

The FDA approved Akeega combination therapy for adults with BRCA2-mutated metastatic castration-sensitive prostate cancer.

The agency said that although the Akeega with prednisone improved outcomes in all patients with HRR mutations, the benefits were driven by those with BRCA2 mutations.

The FDA has greenlit niraparib and abiraterone acetate (AAP; Akeega) with prednisone for the treatment of adults with deleterious or suspected deleterious BRCA2 -mutated metastatic hormone-sensitive ...